Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04068181
Title Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Amgen
Indications

melanoma

Therapies

Pembrolizumab + Talimogene laherparepvec

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.